{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:36:56Z","timestamp":1793320616493,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To investigate the quality of life (QoL) in patients with hypoparathyroidism (hypoPT) compared to the general population and to identify sociodemographic and clinical factors that are associated with symptom burden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with a diagnosis of hypoPT participated in an online survey. Information regarding the survey was distributed by treating physicians or a self-help organization. Quality of life was assessed using the EORTC QLQ-C30 and symptom burden using the Hypoparathyroid Patient Questionnaire (HPQ28). Multivariate linear regression analysis was used to compare QoL of hypoPT patients with the general population (adjusted for age, sex, education)and to identify factors associated with symptom burden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Altogether, 264 hypoPT patients provided information on QoL and symptom burden. HypoPT was associated with worse <jats:italic>cognitive<\/jats:italic> (\u03b2\u2009=\u2009\u221215.9; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and <jats:italic>emotional functioning<\/jats:italic> (\u03b2\u2009=\u2009\u221212.3; <jats:italic>p<\/jats:italic>\u2009=\u20090.04) compared to the general population. The highest symptom burden in hypoPT patients was observed for the domains <jats:italic>loss of vitality<\/jats:italic> (mean: 61.4; SD: 21.9), <jats:italic>pain and cramps<\/jats:italic> (mean: 43.7; SD: 26.5), and <jats:italic>numbness and tingling sensations<\/jats:italic> (mean: 38.9; SD: 30.0). Female gender was associated with a higher symptom burden across all nine domains of the HPQ28, while longer disease duration was associated with a lower symptom burden in <jats:italic>neurovegetative symptoms<\/jats:italic>, <jats:italic>loss of vitality<\/jats:italic>, <jats:italic>depression and anxiety<\/jats:italic>, and <jats:italic>depressive symptoms<\/jats:italic>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>HypoPT patients have impaired QoL compared to the general population. Being female is strongly associated with high symptom burden.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-023-03443-2","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T12:01:41Z","timestamp":1689336101000},"page":"419-426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Impairments in quality of life and predictors of symptom burden in patients with hypoparathyroidism: results from a population-based survey"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7000-8257","authenticated-orcid":false,"given":"Matthias","family":"B\u00fcttner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Krogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heide","family":"Siggelkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"issue":"8","key":"3443_CR1","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1210\/jc.2016-1477","volume":"101","author":"MC Astor","year":"2016","unstructured":"M.C. Astor, K. Lovas, A. Debowska, E.F. Eriksen, J.A. Evang, C. Fossum et al. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J. Clin. Endocrinol. Metab. 101(8), 3045\u20133053 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"3443_CR2","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/jbmr.2004","volume":"28","author":"J Powers","year":"2013","unstructured":"J. Powers, K. Joy, A. Ruscio, H. Lagast, Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J. Bone Min. Res 28(12), 2570\u20132576 (2013)","journal-title":"J. Bone Min. Res"},{"issue":"11","key":"3443_CR3","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/jbmr.1979","volume":"28","author":"L Underbjerg","year":"2013","unstructured":"L. Underbjerg, T. Sikjaer, L. Mosekilde, L. Rejnmark, Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J. Bone Min. Res. 28(11), 2277\u20132285 (2013)","journal-title":"J. Bone Min. Res."},{"issue":"9","key":"3443_CR4","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/jbmr.2501","volume":"30","author":"L Underbjerg","year":"2015","unstructured":"L. Underbjerg, T. Sikjaer, L. Mosekilde, L. Rejnmark, The epidemiology of nonsurgical hypoparathyroidism in Denmark: A nationwide case finding study. J. Bone Min. Res 30(9), 1738\u20131744 (2015)","journal-title":"J. Bone Min. Res"},{"issue":"2","key":"3443_CR5","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-15-0628","volume":"173","author":"J Bollerslev","year":"2015","unstructured":"J. Bollerslev, L. Rejnmark, C. Marcocci, D.M. Shoback, A. Sitges-Serra, W. van Biesen et al. European society of endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur. J. Endocrinol. 173(2), G1\u2013G20 (2015)","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"3443_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMcp0803050","volume":"359","author":"D Shoback","year":"2008","unstructured":"D. Shoback, Clinical practice. Hypoparathyroidism. N. Engl. J. Med 359(4), 391\u2013403 (2008)","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"3443_CR7","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.1210\/clinem\/dgab577","volume":"107","author":"AA Khan","year":"2022","unstructured":"A.A. Khan, L. Rejnmark, M. Rubin, P. Schwarz, T. Vokes, B. Clarke et al. PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism. J. Clin. Endocrinol. Metab. 107(1), e372\u2013e385 (2022)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"3443_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1210\/jc.2017-01555","volume":"103","author":"A Palermo","year":"2018","unstructured":"A. Palermo, A. Santonati, G. Tabacco, D. Bosco, A. Spada, C. Pedone et al. PTH(1-34) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life. J. Clin. Endocrinol. Metab. 103(1), 271\u2013280 (2018)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"3443_CR9","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1210\/jc.2018-02430","volume":"104","author":"G Tabacco","year":"2019","unstructured":"G. Tabacco, Y.D. Tay, N.E. Cusano, J. Williams, B. Omeragic, R. Majeed et al. Quality of life in hypoparathyroidism improves with rhPTH(1-84) throughout 8 years of therapy. J. Clin. Endocrinol. Metab. 104(7), 2748\u20132756 (2019)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"3443_CR10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1210\/jc.2017-01471","volume":"103","author":"TJ Vokes","year":"2018","unstructured":"T.J. Vokes, M. Mannstadt, M.A. Levine, B.L. Clarke, P. Lakatos, K. Chen et al. Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism. J. Clin. Endocrinol. Metab. 103(2), 722\u2013731 (2018)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"3443_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1530\/eje.0.1460215","volume":"146","author":"W Arlt","year":"2002","unstructured":"W. Arlt, C. Fremerey, F. Callies, M. Reincke, P. Schneider, W. Timmermann et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur. J. Endocrinol. 146(2), 215\u2013222 (2002)","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"3443_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12020-017-1377-3","volume":"58","author":"M Buttner","year":"2017","unstructured":"M. Buttner, T.J. Musholt, S. Singer, Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review. Endocrine 58(1), 14\u201320 (2017)","journal-title":"Endocrine"},{"issue":"7","key":"3443_CR13","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/jbmr.2812","volume":"31","author":"T Sikjaer","year":"2016","unstructured":"T. Sikjaer, E. Moser, L. Rolighed, L. Underbjerg, L.S. Bislev, L. Mosekilde et al. Concurrent hypoparathyroidism is associated with impaired physical function and quality of life in hypothyroidism. J. Bone Min. Res 31(7), 1440\u20131448 (2016)","journal-title":"J. Bone Min. Res"},{"issue":"3","key":"3443_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/cen.14701","volume":"97","author":"M Buttner","year":"2022","unstructured":"M. Buttner, D. Krogh, H. Siggelkow, S. Singer, What are predictors of impaired quality of life in patients with hypoparathyroidism? Clin. Endocrinol. (Oxf.) 97(3), 268\u2013275 (2022)","journal-title":"Clin. Endocrinol. (Oxf.)"},{"issue":"7","key":"3443_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4158\/EP13328.OR","volume":"20","author":"N Hadker","year":"2014","unstructured":"N. Hadker, J. Egan, J. Sanders, H. Lagast, B.L. Clarke, Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. Endocr. Pr. 20(7), 671\u2013679 (2014)","journal-title":"Endocr. Pr."},{"issue":"1","key":"3443_CR16","first-page":"e10245","volume":"4","author":"D Wilde","year":"2020","unstructured":"D. Wilde, L. Wilken, B. Stamm, M. Blaschke, C. Heppner, M.L. Chavanon et al. The HPQ-development and first administration of a questionnaire for hypoparathyroid patients. JBMR . 4(1), e10245 (2020)","journal-title":"JBMR ."},{"issue":"1","key":"3443_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-020-00759-8","volume":"15","author":"S Hepsen","year":"2020","unstructured":"S. Hepsen, P. Akhanli, D. Sakiz, M.E. Sencar, B. Ucan, I.O. Unsal et al. The effects of patient and disease-related factors on the quality of life in patients with hypoparathyroidism. Arch. Osteoporos. 15(1), 75 (2020)","journal-title":"Arch. Osteoporos."},{"issue":"7","key":"3443_CR18","first-page":"e10368","volume":"4","author":"D Wilde","year":"2020","unstructured":"D. Wilde, L. Wilken, B. Stamm, C. Heppner, A. Leha, M. Blaschke et al. Quantification of symptom load by a disease-specific questionnaire HPQ 28 and analysis of associated biochemical parameters in patients with postsurgical hypoparathyroidism. JBMR 4(7), e10368 (2020)","journal-title":"JBMR"},{"issue":"4","key":"3443_CR19","first-page":"e10479","volume":"5","author":"CU Jorgensen","year":"2021","unstructured":"C.U. Jorgensen, P. Homoe, M. Dahl, M.F. Hitz, Postoperative chronic hypoparathyroidism and quality of life after total thyroidectomy. JBMR . 5(4), e10479 (2021)","journal-title":"JBMR ."},{"key":"3443_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","volume":"107","author":"S Nolte","year":"2019","unstructured":"S. Nolte, G. Liegl, M.A. Petersen, N.K. Aaronson, A. Costantini, P.M. Fayers et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur. J. Cancer 107, 153\u2013163 (2019)","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"3443_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"N.K. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, N.J. Duez et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85(5), 365\u2013376 (1993)","journal-title":"J. Natl. Cancer Inst."},{"key":"3443_CR22","unstructured":"P.M. A.N. Fayers, K. Bjordal, M. Groenvold, D. Curran, A. Bottomley, on behalf of the EORTC Quality of Life Group The EORTC QLQ-C30 Scoring Manual (3rd Edition): European Organisation for Research and Treatment of Cancer. Brussels; 2001."},{"issue":"3","key":"3443_CR23","first-page":"319","volume":"62","author":"AJ Arneiro","year":"2018","unstructured":"A.J. Arneiro, B.C.C. Duarte, R.M. Kulchetscki, V.B.S. Cury, M.P. Lopes, B.S. Kliemann et al. Self-report of psychological symptoms in hypoparathyroidism patients on conventional therapy. Arch. Endocrinol. Metab. 62(3), 319\u2013324 (2018)","journal-title":"Arch. Endocrinol. Metab."},{"issue":"12","key":"3443_CR24","doi-asserted-by":"publisher","first-page":"dgaa597","DOI":"10.1210\/clinem\/dgaa597","volume":"105","author":"M Buttner","year":"2020","unstructured":"M. Buttner, L.D. Locati, M. Pinto, C. Araujo, I.M. Tomaszewska, N. Kiyota, et al. Quality of life in patients with hypoparathyroidism after treatment for thyroid cancer. J. Clin. Endocrinol. Metab. 105(12), dgaa597 (2020)","journal-title":"J. Clin. Endocrinol. Metab"},{"issue":"3-4","key":"3443_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/10606820213682","volume":"8","author":"TB Usdin","year":"2002","unstructured":"T.B. Usdin, T.I. Bonner, S.R. Hoare, The parathyroid hormone 2 (PTH2) receptor. Recept Channels 8(3-4), 211\u2013218 (2002)","journal-title":"Recept Channels"},{"issue":"1","key":"3443_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.neuroscience.2009.04.054","volume":"162","author":"AG Bago","year":"2009","unstructured":"A.G. Bago, E. Dimitrov, R. Saunders, L. Seress, M. Palkovits, T.B. Usdin et al. Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human. Neuroscience 162(1), 128\u2013147 (2009)","journal-title":"Neuroscience"},{"key":"3443_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.physbeh.2017.09.005","volume":"181","author":"B Gellen","year":"2017","unstructured":"B. Gellen, D. Zelena, T.B. Usdin, A. Dobolyi, The parathyroid hormone 2 receptor participates in physiological and behavioral alterations of mother mice. Physiol. Behav. 181, 51\u201358 (2017)","journal-title":"Physiol. Behav."},{"issue":"2","key":"3443_CR28","first-page":"227","volume":"106","author":"S Balabanov","year":"1984","unstructured":"S. Balabanov, U. Tollner, H.P. Richter, F. Pohlandt, G. Gaedicke, W.M. Teller, Immunoreactive parathyroid hormone, calcium, and magnesium in human cerebrospinal fluid. Acta Endocrinol. (Copenh) 106(2), 227\u2013233 (1984)","journal-title":"Acta Endocrinol. (Copenh)"},{"issue":"2","key":"3443_CR29","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1210\/endo.142.2.7955","volume":"142","author":"P Divieti","year":"2001","unstructured":"P. Divieti, N. Inomata, K. Chapin, R. Singh, H. Juppner, F.R. Bringhurst, Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells. Endocrinology 142(2), 916\u2013925 (2001)","journal-title":"Endocrinology"},{"issue":"2","key":"3443_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/pon.500","volume":"10","author":"EG Eakin","year":"2001","unstructured":"E.G. Eakin, L.A. Strycker, Awareness and barriers to use of cancer support and information resources by HMO patients with breast, prostate, or colon cancer: patient and provider perspectives. Psychooncology 10(2), 103\u2013113 (2001)","journal-title":"Psychooncology"},{"issue":"1","key":"3443_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3197-4","volume":"18","author":"T Jansen","year":"2018","unstructured":"T. Jansen, J. Rademakers, G. Waverijn, R. Verheij, R. Osborne, M. Heijmans, The role of health literacy in explaining the association between educational attainment and the use of out-of-hours primary care services in chronically ill people: a survey study. BMC Health Serv. Res 18(1), 394 (2018)","journal-title":"BMC Health Serv. Res"},{"issue":"12","key":"3443_CR32","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1007\/s00268-022-06730-7","volume":"46","author":"SL Hillary","year":"2022","unstructured":"S.L. Hillary, J.E. Chooi, J. Wadsley, J.D. Newell-Price, N.J. Brown, S.P. Balasubramanian, Quality of life in post-surgical hypoparathyroidism (PoSH) in thyroid and parathyroid surgery. World J. Surg. 46(12), 3025\u20133033 (2022)","journal-title":"World J. Surg."},{"issue":"2","key":"3443_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cen.14128","volume":"92","author":"H Siggelkow","year":"2020","unstructured":"H. Siggelkow, B.L. Clarke, J. Germak, C. Marelli, K. Chen, H. Dahl-Hansen et al. Burden of illness in not adequately controlled chronic hypoparathyroidism: Findings from a 13-country patient and caregiver survey. Clin. Endocrinol. (Oxf.) 92(2), 159\u2013168 (2020)","journal-title":"Clin. Endocrinol. (Oxf.)"},{"issue":"11","key":"3443_CR34","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/13696998.2019.1624081","volume":"22","author":"K Chen","year":"2019","unstructured":"K. Chen, A. Krasner, N. Li, C.Q. Xiang, T. Totev, J. Xie, Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately vs not adequately controlled disease: a multi-country chart review. J. Med Econ. 22(11), 1141\u20131152 (2019)","journal-title":"J. Med Econ."},{"issue":"2","key":"3443_CR35","doi-asserted-by":"publisher","first-page":"bvaa181","DOI":"10.1210\/jendso\/bvaa181","volume":"5","author":"MB Zanchetta","year":"2021","unstructured":"M.B. Zanchetta, D. Robbiani, B. Oliveri, E. Giacoia, A. Frigeri, S. Kallsbrum et al. Hipopara-Red, Real Life Experience in 322 Patients With Hypoparathyroidism. J. Endocr. Soc. 5(2), bvaa181 (2021)","journal-title":"J. Endocr. Soc."},{"key":"3443_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/CMAR.S397198","volume":"15","author":"M Koch","year":"2023","unstructured":"M. Koch, T. Rothammer, F. Rasch, K. Muller, J. Braess, M. Koller et al. Gender differences in symptom burden, functional performance and global quality of life of lung cancer patients receiving inpatient versus outpatient treatment. Cancer Manag Res 15, 175\u2013183 (2023)","journal-title":"Cancer Manag Res"},{"issue":"2","key":"3443_CR37","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/ehf2.14260","volume":"10","author":"J Tapia","year":"2022","unstructured":"J. Tapia, M. Basalo, C. Enjuanes, E. Calero, N. Jose, M. Ruiz, et al. Psychosocial factors partially explain gender differences in health-related quality of life in heart failure patients. ESC Heart Fail. 10(2), 1090\u20131102 (2022)","journal-title":"ESC Heart Fail"},{"issue":"7","key":"3443_CR38","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/ndt\/gfad023","volume":"38","author":"DMJ Veltkamp","year":"2023","unstructured":"D.M.J. Veltkamp, Y. Wang, Y. Meuleman, F.W. Dekker, W.M. Michels, P.J.M. van der Boog, et al. Age and gender differences in symptom experience and health-related quality of life in kidney transplant recipients: a cross-sectional study. Nephrol Dial Transpl. 38(7), 1707\u20131718 (2023)","journal-title":"Nephrol Dial Transpl"},{"issue":"9","key":"3443_CR39","first-page":"743","volume":"38","author":"Z Lyons","year":"2009","unstructured":"Z. Lyons, A. Janca, Diagnosis of male depression-does general practitioner gender play a part? Aust. Fam. Phys. 38(9), 743\u2013746 (2009)","journal-title":"Aust. Fam. Phys."},{"issue":"Suppl","key":"3443_CR40","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/0378-5122(96)01015-8","volume":"23","author":"HK Vaananen","year":"1996","unstructured":"H.K. Vaananen, P.L. Harkonen, Estrogen and bone metabolism. Maturitas 23(Suppl), S65\u2013S69 (1996)","journal-title":"Maturitas"},{"issue":"6","key":"3443_CR41","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jpainsymman.2007.01.011","volume":"34","author":"OM Fredheim","year":"2007","unstructured":"O.M. Fredheim, P.C. Borchgrevink, T. Saltnes, S. Kaasa, Validation and comparison of the health-related quality-of-life instruments EORTC QLQ-C30 and SF-36 in assessment of patients with chronic nonmalignant pain. J. Pain. Symptom Manag. 34(6), 657\u2013665 (2007)","journal-title":"J. Pain. Symptom Manag."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03443-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03443-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03443-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T07:08:53Z","timestamp":1696057733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03443-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["3443"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03443-2","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MB reports speaker fees from Lilly and Takeda outside the submitted work. DK has nothing to disclose. HS Advisory boards: MSD, Lilly, Amgen, Servier, Takeda, UCB, Kyowa Kirin. Speaker fees: MSD, Lilly, Amgen, GSK, Servier, Takeda, Alexion, Kyowa Kirin, UCB, Sandoz, Sanofi Aventis. Research support: Takeda. SS received honoraria from Lilly and Eisai, all outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"According to the design of the study, no Ethics Committee approval was needed (confirmed by the Ethics-Committee of the Landes\u00e4rztekammer Rhineland-Palatinate).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}